mazindol has been researched along with Obesity in 107 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 9.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "In a single blind study 25 out patients with exogenous obesity were treated for 6 weeks with Mazindol (2 mg one hour before lunch)." | 9.04 | [Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)]. ( Mies, R, 1976) |
| "The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients." | 8.95 | Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. ( Correr, CJ; Fernandez-Llimos, F; Lucchetta, RC; Otuki, MF; Pontarolo, R; Radominski, RB; Riveros, BS, 2017) |
| "To assess the validity of the perceptions that appetite-suppressant drugs are ineffective, potentially addictive, and fraught with side effects, we reviewed the effectiveness and safety of two such drugs with purported low abuse potential in the treatment of obesity: mazindol and fenfluramine hydrochloride." | 8.78 | An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. ( Imperiale, TF; Stahl, KA, 1993) |
| "Biochemical and morphological studies were made on the role of mazindol in treatment of obesity in mice induced by gold thioglucose (GTG) injection." | 7.67 | Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection. ( Kawano-Takahashi, Y; Ohminaji, H; Okuda, H; Ubagai, E, 1984) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 5.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "Mazindol was added to the diet at the level of 0." | 5.27 | [Effect of mazindol on obesity induced by administration of gold thioglucose]. ( Matsuoka, E; Ohminami, K; Okuda, H; Shimizu, D; Takahashi, Y, 1984) |
| " Changes in carbohydrate metabolism after chronic administration of mazindol are entirely consistent with weight loss, although a separate effect of the drug cannot be excluded." | 5.25 | Effects of mazindol on carbohydrate and insulin metabolism in obesity. ( Harrison, LC; King-Roach, AP; Sandy, KC, 1975) |
| "To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss." | 5.19 | A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014) |
| "We conducted a double-blind test to examine whether or not the addition of mazindol, an appetite suppressor, to combined diet therapy [low-calorie diet + Optifast: 4600-3928kj(1100-940 kcal)/day] enhances the weight-reduction effect and reduces dropout from treatment in women with severe obesity." | 5.07 | Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women. ( Kondo, M; Sakane, N; Umekawa, T; Wakabayashi, Y; Yoshida, T; Yoshioka, K, 1994) |
| "Mazindol, diethylpropion, and a placebo were compared with behavioral therapy for effectiveness in producing weight reduction in an outpatient obesity clinic." | 5.04 | Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs. ( Atkinson, RL; Bray, GA; Dahms, WT; Greenway, FL; Hamilton, K; Molitch, ME, 1978) |
| "The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients." | 4.95 | Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. ( Correr, CJ; Fernandez-Llimos, F; Lucchetta, RC; Otuki, MF; Pontarolo, R; Radominski, RB; Riveros, BS, 2017) |
| "To assess the validity of the perceptions that appetite-suppressant drugs are ineffective, potentially addictive, and fraught with side effects, we reviewed the effectiveness and safety of two such drugs with purported low abuse potential in the treatment of obesity: mazindol and fenfluramine hydrochloride." | 4.78 | An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. ( Imperiale, TF; Stahl, KA, 1993) |
| "Mazindol is a sympathomimetic amine, widely used as an anorectic agent in the treatment of obesity." | 3.80 | Effects of acute administration of mazindol on brain energy metabolism in adult mice. ( Bez, GD; Daufenbach, JF; Ferreira, GK; Gomes, LM; Gonçalves, CL; Jeremias, IC; Rezin, GT; Scaini, G; Streck, EL; Zugno, AI, 2014) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Anorectic drugs such as mazindol bind to a class of low-affinity, sodium-sensitive sites in the brain which are affected by ambient glucose concentrations and a predisposition to develop diet-induced obesity (DIO)." | 3.69 | Location and effect of obesity on putative anorectic binding sites in the rat brain. ( Dunn-Meynell, AA; Levin, BE, 1997) |
| "Biochemical and morphological studies were made on the role of mazindol in treatment of obesity in mice induced by gold thioglucose (GTG) injection." | 3.67 | Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection. ( Kawano-Takahashi, Y; Ohminaji, H; Okuda, H; Ubagai, E, 1984) |
| "When mazindol was administered, GH levels increased somewhat in some obese patients during ITTs, while T3 RIA and rT3 RIA decreased in some patients." | 2.65 | Endocrine studies with mazindol in obese patients. ( Dolecek, R, 1980) |
| "Because obesity is highly stigmatized, any effective treatment should be made available to improve quality of life and self-image." | 2.47 | Pharmacology in health foods:merits and demerits of food with health claims for the prevention of metabolic syndrome. ( Sakane, N, 2011) |
| "Obesity is a major cause of increased morbidity and mortality among patients with PWS." | 2.44 | [Therapeutical approach of obesity in Prader-Willi Syndrome]. ( Almeida, MQ; Carvalho, DF; Cercato, C; Halpern, A; Mancini, MC, 2007) |
| " We examined the effects of mazindol on 1) body weight, appetite, and abnormalities of obesity-related diseases in long-term use 2) maintenance of the reduced body weight after very-low-calorie diet (VLCD) therapy 3) combined use with VLCD therapy and, 4) inhibition of body weight gain in Prader-Willi syndrome." | 2.39 | Clinical studies with mazindol. ( Inoue, S, 1995) |
| " In some patients, weight regain may be prevented by giving the drug long term but the complications of long-term administration have yet to be evaluated." | 2.37 | The current status of antiobesity drugs. ( Farquhar, DL; Galloway, SM; Munro, JF, 1984) |
| "Obesity is one of the pathologies with ever-increasing prevalence in modern societies." | 1.31 | [The role of pharmacotherapy for treatment of obesity in adults]. ( Czupryniak, L; Drzewoski, J, 2000) |
| "Mazindol was unstable in plasma samples left at rt and 4 degrees C." | 1.31 | High performance liquid chromatographic determination of mazindol in human plasma. ( Kaddoumi, A; Kono, M; Mori, M; Nakashima, K; Nanashima, K, 2001) |
| "Mazindol has an indirect sympathomimetic action and is known to cause urogenital side effects such as urinary retention and testicular pain." | 1.30 | Semen-like urethral discharge during the use of mazindol. ( Meyboom, RH; van Puijenbroek, EP, 1998) |
| "Mazindol was added to the diet at the level of 0." | 1.27 | [Effect of mazindol on obesity induced by administration of gold thioglucose]. ( Matsuoka, E; Ohminami, K; Okuda, H; Shimizu, D; Takahashi, Y, 1984) |
| "Mazindol was well tolerated, only 29 patients dropped out of the trial because of side-effects." | 1.25 | A multi-centre trial of mazindol ('Teronac') in general practice in Ireland. ( Evans, ER; Wallace, MG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 77 (71.96) | 18.7374 |
| 1990's | 14 (13.08) | 18.2507 |
| 2000's | 9 (8.41) | 29.6817 |
| 2010's | 6 (5.61) | 24.3611 |
| 2020's | 1 (0.93) | 2.80 |
| Authors | Studies |
|---|---|
| Arguelles-Tello, FA | 1 |
| Kammar-García, A | 1 |
| Trejo-Jasso, CA | 1 |
| Huerta-Cruz, JC | 1 |
| Barranco-Garduño, LM | 1 |
| Rocha-González, HI | 1 |
| Reyes-García, JG | 1 |
| Lucchetta, RC | 2 |
| Riveros, BS | 2 |
| Pontarolo, R | 2 |
| Radominski, RB | 2 |
| Otuki, MF | 2 |
| Fernandez-Llimos, F | 2 |
| Correr, CJ | 2 |
| Suplicy, H | 1 |
| Boguszewski, CL | 1 |
| dos Santos, CM | 1 |
| do Desterro de Figueiredo, M | 1 |
| Cunha, DR | 1 |
| Radominski, R | 1 |
| Gonçalves, CL | 1 |
| Scaini, G | 1 |
| Rezin, GT | 1 |
| Jeremias, IC | 1 |
| Bez, GD | 1 |
| Daufenbach, JF | 1 |
| Gomes, LM | 1 |
| Ferreira, GK | 1 |
| Zugno, AI | 1 |
| Streck, EL | 1 |
| Sakane, N | 2 |
| Mori, Y | 1 |
| Arterburn, D | 3 |
| DeLaet, D | 1 |
| Flum, D | 1 |
| Mancini, MC | 2 |
| Halpern, A | 2 |
| Carvalho, DF | 1 |
| Cercato, C | 1 |
| Almeida, MQ | 1 |
| Galloway, SM | 1 |
| Farquhar, DL | 1 |
| Munro, JF | 4 |
| Ohminami, K | 1 |
| Matsuoka, E | 1 |
| Takahashi, Y | 1 |
| Shimizu, D | 1 |
| Okuda, H | 2 |
| Kawano-Takahashi, Y | 1 |
| Ohminaji, H | 1 |
| Ubagai, E | 1 |
| Inoue, S | 3 |
| Egawa, M | 2 |
| Satoh, S | 2 |
| Rihmer, Z | 1 |
| Révai, K | 1 |
| Arató, M | 1 |
| Perényi, A | 1 |
| Komorowski, JM | 1 |
| Zwaigzne-Raczyńska, J | 3 |
| Owczarczyk, I | 1 |
| Gołebiowska, M | 3 |
| Zarzycki, J | 1 |
| Altschuler, S | 1 |
| Conte, A | 1 |
| Sebok, M | 1 |
| Marlin, RL | 1 |
| Winick, C | 1 |
| Dolecek, R | 3 |
| Hopkins, SJ | 1 |
| Zahorska-Markiewicz, B | 4 |
| Hasik, J | 2 |
| Gawlak, E | 1 |
| Tycowa, M | 2 |
| Vasiukova, EA | 2 |
| Granovskaia-Tsvetkova, AM | 2 |
| Lapshin, VP | 1 |
| Olefirenko, VT | 1 |
| Vinogradova, IM | 1 |
| Chlebna-Sokoł, D | 2 |
| Mastalska, A | 2 |
| Kobierska, I | 1 |
| Konopińska, A | 1 |
| Małek, M | 1 |
| van Seters, AP | 1 |
| Bouwhuis-Hoogerwerf, ML | 1 |
| Goslings, BM | 1 |
| van Nieuwkoop, L | 1 |
| van Slooten, H | 1 |
| Struijk-Wielinga, T | 1 |
| Marova, EI | 1 |
| Piskunova, GG | 1 |
| Korotkova, VD | 1 |
| Mokina, MV | 1 |
| Sonka, J | 1 |
| Límanová, Z | 1 |
| Zbirková, A | 1 |
| Kratochvíl, O | 1 |
| Ikeda, Y | 1 |
| Yoshida, T | 1 |
| Umekawa, T | 1 |
| Yoshioka, K | 1 |
| Kondo, M | 1 |
| Wakabayashi, Y | 1 |
| Levin, BE | 2 |
| Brown, KL | 1 |
| Vincent, G | 1 |
| Stahl, KA | 1 |
| Imperiale, TF | 1 |
| Miralles, A | 1 |
| Ribas, C | 1 |
| Olmos, G | 1 |
| García-Sevilla, JA | 1 |
| Rachagan, SP | 1 |
| Meinders, AE | 1 |
| Toornvliet, AC | 1 |
| Pijl, H | 1 |
| Dunn-Meynell, AA | 1 |
| van Puijenbroek, EP | 1 |
| Meyboom, RH | 1 |
| Ryan, DH | 2 |
| Bray, GA | 4 |
| Helmcke, F | 1 |
| Sander, G | 1 |
| Volaufova, J | 1 |
| Greenway, F | 1 |
| Subramaniam, P | 1 |
| Glancy, DL | 1 |
| Greenway, FL | 3 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Toda, Y | 1 |
| Kobayashi, T | 1 |
| Czupryniak, L | 1 |
| Drzewoski, J | 1 |
| Ueno, M | 1 |
| Kaddoumi, A | 1 |
| Mori, M | 1 |
| Nanashima, K | 1 |
| Kono, M | 1 |
| Nakashima, K | 1 |
| Rath, R | 3 |
| Vondra, K | 3 |
| Bass, A | 2 |
| Kujalova, V | 2 |
| Wenkeova, J | 2 |
| Murphy, JE | 1 |
| Donald, JF | 1 |
| Molla, AL | 1 |
| Crowder, D | 1 |
| Maclay, WP | 1 |
| Wallace, MG | 2 |
| Walker, BR | 1 |
| Ballard, IM | 1 |
| Gold, JA | 1 |
| Riesco, J | 1 |
| Troncoso, G | 1 |
| Costamaillere, L | 1 |
| Rodríguez, J | 1 |
| Slama, G | 1 |
| Selmi, A | 1 |
| Hautecouverture, M | 1 |
| Tchobroutsky, G | 1 |
| Atkinson, RL | 2 |
| Dahms, WT | 2 |
| Molitch, ME | 2 |
| Hamilton, K | 2 |
| Rodin, J | 1 |
| Baird, IM | 1 |
| Howard, AN | 1 |
| Kocemba, J | 1 |
| Kawecka-Jaszcz, K | 1 |
| Zdichynec, B | 1 |
| Rechmani, BA | 1 |
| Tatoń, J | 1 |
| Czech, A | 1 |
| Koliński, P | 1 |
| Podwysocka, G | 1 |
| Johnson, WG | 1 |
| Hughes, JR | 1 |
| Siani, V | 1 |
| Baritussio, A | 2 |
| Enzi, G | 2 |
| Rigon, G | 1 |
| Molinari, M | 1 |
| Inelmen, EM | 1 |
| Crepaldi, G | 2 |
| Gryczka, AZ | 1 |
| Paluszak, J | 1 |
| Wallace, AG | 1 |
| Siciński, A | 1 |
| Stasiakowa, L | 1 |
| Bleehen, SS | 1 |
| Edwards, IR | 1 |
| Clark, RG | 1 |
| Haugen, HN | 1 |
| Reil, P | 1 |
| Skarpová, O | 1 |
| Závada, M | 1 |
| Kreze, A | 1 |
| Velemínsky, J | 1 |
| Toman, A | 1 |
| Husmann, F | 1 |
| Linke, H | 1 |
| Miach, PJ | 1 |
| Thomson, W | 1 |
| Doyle, AE | 1 |
| Louis, WJ | 1 |
| Bandisode, MS | 1 |
| Boshell, BR | 1 |
| Delitala, G | 1 |
| Alagna, S | 1 |
| Masala, A | 1 |
| Felt, V | 2 |
| Nedvídková, J | 1 |
| Escher, M | 1 |
| Sanders, M | 1 |
| Breidahl, H | 1 |
| Mies, R | 1 |
| Jenny, S | 1 |
| Zimmermann, KG | 1 |
| Radielovic, P | 1 |
| Bühlmann, AA | 1 |
| Marchiori, E | 1 |
| Sedgwick, JP | 1 |
| Smith, RG | 1 |
| Innes, JA | 1 |
| Jackson, WP | 1 |
| Vinik, AI | 1 |
| Woodhouse, SP | 1 |
| Nye, ER | 1 |
| Anderson, K | 1 |
| Rawlings, J | 1 |
| Heber, KR | 1 |
| Evans, ER | 1 |
| Harrison, LC | 1 |
| King-Roach, AP | 1 |
| Sandy, KC | 1 |
| Ishikawa, T | 1 |
| Nakaya, N | 1 |
| Nakamura, H | 1 |
| Goto, Y | 2 |
| Angel, I | 1 |
| Hauger, RL | 1 |
| Giblin, BA | 1 |
| Paul, SM | 1 |
| Saito, M | 1 |
| Suzuki, H | 1 |
| Kumahara, Y | 1 |
| Abe, M | 1 |
| Kumagai, A | 1 |
| Shizume, K | 1 |
| Guazzelli, R | 1 |
| Piazzini, M | 1 |
| Conti, C | 1 |
| Papi, L | 1 |
| Strazzulla, G | 1 |
| Matassi, L | 1 |
| Jonderko, K | 2 |
| Kucio, C | 4 |
| Skrzypek, D | 2 |
| Ishii, J | 1 |
| Piskorska, D | 1 |
| Semenowicz-Siuda, K | 1 |
| Waluga, M | 1 |
| Silverstone, T | 1 |
| Cluysenaer, OJ | 1 |
| Tjoeng, MM | 1 |
| Usami, M | 1 |
| Seino, Y | 1 |
| Nishi, S | 1 |
| Nakahara, H | 1 |
| Ikeda, M | 1 |
| Matsukura, S | 1 |
| Imura, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to failure to enroll) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for mazindol and Obesity
| Article | Year |
|---|---|
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
Topics: Appetite Depressants; Diethylpropion; Humans; Mazindol; Obesity; Overweight; Publication Bias; Repro | 2017 |
Pharmacology in health foods:merits and demerits of food with health claims for the prevention of metabolic syndrome.
Topics: Anti-Obesity Agents; Consumer Health Information; Food, Organic; Humans; Japan; Mazindol; Metabolic | 2011 |
[Mazindol].
Topics: Appetite Depressants; Humans; Mazindol; Metabolic Syndrome; Obesity | 2011 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O | 2003 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O | 2004 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty; | 2005 |
Pharmacological treatment of obesity.
Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Ene | 2006 |
[Therapeutical approach of obesity in Prader-Willi Syndrome].
Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Child; Child, Preschool; Female; Fluoxetine; Fru | 2007 |
The current status of antiobesity drugs.
Topics: Adult; Amphetamine; Appetite Depressants; Body Weight; Child; Diethylpropion; Dose-Response Relation | 1984 |
[Therapy of obesity using appetite depressants].
Topics: Appetite Depressants; Clinical Trials as Topic; Double-Blind Method; Humans; Mazindol; Multicenter S | 1995 |
An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity.
Topics: Adult; Body Weight; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Humans; Mal | 1993 |
Clinical studies with mazindol.
Topics: Appetite Depressants; Diet, Reducing; Humans; Japan; Mazindol; Obesity | 1995 |
[Drug treatment of obesity].
Topics: Adult; Appetite Depressants; Female; Fenfluramine; Humans; Leptin; Male; Mazindol; Obesity; Proteins | 1996 |
[Hyperlipidemia with obesity].
Topics: Body Mass Index; Coronary Disease; Diagnosis, Differential; Diet, Fat-Restricted; Diet, Reducing; Ex | 2001 |
Clinical aspects of the treatment of obesity by drugs: a review.
Topics: Amphetamines; Appetite Depressants; Clinical Trials as Topic; Diethylpropion; Drug Tolerance; Female | 1979 |
Treatment of obesity. Appetite suppressant drugs and intestinal by-pass surgery.
Topics: Amphetamines; Appetite Depressants; Diethylpropion; Fenfluramine; Humans; Intestine, Small; Mazindol | 1976 |
Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
Topics: Animals; Eating; Female; Humans; Hypothalamus; Japan; Mazindol; Obesity | 1992 |
Clinical use of appetite suppressants.
Topics: Amphetamines; Appetite Depressants; Body Weight; Diethylpropion; Double-Blind Method; Drug Tolerance | 1986 |
47 trials available for mazindol and Obesity
| Article | Year |
|---|---|
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglyc | 2022 |
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die | 2014 |
Three controlled trials of weight loss with phenylpropanolamine.
Topics: Adolescent; Adult; Appetite Depressants; Blood Pressure; Body Weight; Caffeine; Clinical Trials as T | 1982 |
Endocrine studies with mazindol in obese patients.
Topics: Adolescent; Adult; Aged; Blood Glucose; Female; Follicle Stimulating Hormone; Growth Hormone; Hormon | 1980 |
[Salivary test as the index of appetite inhibition during treatment of obesity (author's transl)].
Topics: Appetite; Clinical Trials as Topic; Female; Humans; Indoles; Mazindol; Obesity; Saliva; Secretory Ra | 1980 |
[Treatment of simple obesity with mazindol under sanatorium conditions].
Topics: Adolescent; Adult; Clinical Trials as Topic; Diet, Reducing; Exercise Therapy; Female; Health Resort | 1980 |
[Treatment of obesity].
Topics: Adult; Balneology; Body Weight; Clinical Trials as Topic; Diet, Reducing; Female; Follow-Up Studies; | 1981 |
[The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)].
Topics: Adolescent; Body Weight; Child; Clinical Trials as Topic; Diet, Reducing; Female; Humans; Indoles; M | 1981 |
[Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
Topics: Adolescent; Appetite; Child; Clinical Trials as Topic; Humans; Indoles; Mazindol; Obesity; Placebos | 1981 |
[Long-term treatment of patients with obesity using mazindol and a reducing diet].
Topics: Adolescent; Adult; Appetite Depressants; Diet, Reducing; Double-Blind Method; Drug Evaluation; Femal | 1982 |
Effects of diet, exercise and anorexigenic drugs on serum thyroid hormones.
Topics: Appetite Depressants; Diet, Reducing; Female; Humans; Mazindol; Obesity; Phenmetrazine; Phentermine; | 1980 |
Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women.
Topics: Adult; Blood Glucose; Blood Pressure; Cholesterol; Diet Therapy; Double-Blind Method; Eating; Exerci | 1994 |
The usefulness of walking for preventing sarcopenia in dieting postmenopausal women complaining of knee pain.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Appetite Depressants; Body Composition; Combined Moda | 2000 |
A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
Topics: Adult; Diethylpropion; Female; Humans; Male; Mazindol; Middle Aged; Obesity; Weight Loss | 1975 |
A multi-centre general practice trial of mazindol in the treatment of obesity.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Family Practice; Female; Humans; Indoles; Male; M | 1977 |
A multicentre study comparing mazindol and placebo in obese patients.
Topics: Adolescent; Adult; Aged; Body Weight; Clinical Trials as Topic; Humans; Indoles; Mazindol; Middle Ag | 1977 |
[Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
Topics: Administration, Oral; Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Met | 1977 |
[Effects of mazindol on some parameters of energy metabolism regulation in weight reduction of obese subjects (author's transl)].
Topics: Adult; Clinical Trials as Topic; Energy Metabolism; Female; Humans; Indoles; Mazindol; Middle Aged; | 1978 |
Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
Topics: Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind M | 1978 |
Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial.
Topics: Adolescent; Adult; Allied Health Personnel; California; Clinical Trials as Topic; Double-Blind Metho | 1977 |
A double-blind trial of mazindol using a very low calorie formula diet.
Topics: Adolescent; Adult; Clinical Trials as Topic; Diet, Reducing; Dizziness; Double-Blind Method; Drug Ev | 1977 |
[Use of mazindol in the dietetic treatment of obesity in patients with essential hypertension].
Topics: Adult; Clinical Trials as Topic; Female; Humans; Hypertension; Indoles; Male; Mazindol; Middle Aged; | 1978 |
[Modification of serum lipid values and of the neurovegetative equilibrium in subjects under mazindol therapy].
Topics: Adult; Autonomic Nervous System; Clinical Trials as Topic; Female; Humans; Hyperlipidemias; Indoles; | 1979 |
Clinical aspects of the treatment of obesity by drugs: a review.
Topics: Amphetamines; Appetite Depressants; Clinical Trials as Topic; Diethylpropion; Drug Tolerance; Female | 1979 |
[Comparison of the anorectic effect of mazindol and placebo in obesity].
Topics: Appetite; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Indoles; Male; Mazindol; Ob | 1979 |
Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs.
Topics: Appetite Depressants; Behavior Therapy; Cost-Benefit Analysis; Diethylpropion; Emotions; Feeding Beh | 1978 |
Mazindol: its efficacy and mode of action in generating weight loss.
Topics: Adult; Body Weight; Double-Blind Method; Eating; Female; Humans; Indoles; Male; Mazindol; Obesity | 1979 |
AN 448 Sandoz (Mazindol) in the treatment of obesity.
Topics: Body Weight; Clinical Trials as Topic; Diet, Reducing; Humans; Indoles; Mazindol; Obesity; Placebos | 1976 |
[Mazindol in the treatment of simple obesity].
Topics: Adult; Body Weight; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indoles; Male; Mazind | 1976 |
[Teronac in the treatment of obesity].
Topics: Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indoles; Male; Mazindol; Obesity | 1976 |
Double blind cross-over study of a new appetite suppressant AN 448.
Topics: Appetite; Blood Pressure; Body Weight; Clinical Trials as Topic; Drug Evaluation; Female; Humans; In | 1975 |
[Mazindol in the treatment of obese diabetic patients].
Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Humans; Indoles; Male; | 1976 |
[Results in the treatment of obesity by Mazindol (AN 448 Sandoz) in hospitalized subjects using the method of double-blind trial (author's transl)].
Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Female; Hospitalization; Humans; Indoles; Mazindol | 1976 |
[Mazindol (Teronac) in the treatment of predominant by food-dependent obesity].
Topics: Clinical Trials as Topic; Diet; Drug Evaluation; Humans; Indoles; Mazindol; Obesity | 1976 |
[Overweight as a therapeutic problem. Experience with the appetite depressant Mazindol].
Topics: Clinical Trials as Topic; Humans; Indoles; Mazindol; Obesity | 1976 |
Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Hypertension; Indoles; Male; Mazindol; Middle | 1976 |
Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diazepam; Drug Evaluation; Female; Glucose | 1975 |
[Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].
Topics: Adolescent; Adult; Chemical Phenomena; Chemistry; Female; Humans; Indoles; Male; Mazindol; Middle Ag | 1976 |
Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity.
Topics: Adolescent; Adult; Anxiety; Diet, Reducing; Drug Evaluation; Glucose Tolerance Test; Humans; Indoles | 1976 |
[Mazindol, an anorectic of a new series, in the treatment of obesity (author's transl)].
Topics: Adult; Appetite Depressants; Clinical Trials as Topic; Drug Evaluation; Humans; Indoles; Mazindol; O | 1975 |
Maziniol in the treatment of obesity.
Topics: Body Weight; Clinical Trials as Topic; Constipation; Humans; Indoles; Mazindol; Obesity; Placebos; S | 1975 |
Double-blind evaluation of mazindol in refractory obesity.
Topics: Appetite; Body Weight; Clinical Trials as Topic; Female; Humans; Indoles; Mazindol; Obesity; Placebo | 1975 |
Letter: Drugs in obesity.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Humans; Indoles; Mazindol; Obesity; Placebos | 1975 |
A double blind controlled trial of a new anorectic agent AN448.
Topics: Appetite Depressants; Body Weight; Cholesterol; Clinical Trials as Topic; Humans; Imidazoles; Indole | 1975 |
Double-blind trial of mazindol in overweight patients.
Topics: Adult; Clinical Trials as Topic; Family Practice; Humans; Indoles; Mazindol; Obesity; Placebos | 1975 |
Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
Topics: Animals; Eating; Female; Humans; Hypothalamus; Japan; Mazindol; Obesity | 1992 |
Slowed gastric evacuation accounts for the reduction of food intake by anorectic drugs.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Feeding Behavior; Female; Gastric Emptying; Hu | 1988 |
44 other studies available for mazindol and Obesity
| Article | Year |
|---|---|
Diethylpropion and mazindol: An end to the discussion?
Topics: Amphetamines; Appetite Depressants; Brazil; Cyclobutanes; Diethylpropion; Drug Approval; Humans; Maz | 2017 |
Effects of acute administration of mazindol on brain energy metabolism in adult mice.
Topics: Animals; Brain; Central Nervous System Stimulants; Energy Metabolism; Male; Mazindol; Mice; Obesity | 2014 |
[Effect of mazindol on obesity induced by administration of gold thioglucose].
Topics: Adipose Tissue; Alanine Transaminase; Animals; Aurothioglucose; Body Weight; Cilia; Eating; Gold; In | 1984 |
Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection.
Topics: Adipose Tissue; Administration, Oral; alpha-Glucosidases; Animals; Aurothioglucose; Body Weight; Cho | 1984 |
[Effects of an anorexiant, mazindol, on metabolic abnormalities of rats with ventromedial hypothalamic lesions].
Topics: Animals; Body Weight; Eating; Female; Indoles; Lipid Metabolism; Liver; Mazindol; Obesity; Organ Siz | 1984 |
Two case reports of mazindol-induced depression.
Topics: Adult; Depressive Disorder; Female; Humans; Indoles; Mazindol; Obesity | 1984 |
[Effect of mazindol (teronac) on various hormonal indicators in children with simple obesity].
Topics: Adolescent; Blood Glucose; Child; Female; Humans; Indoles; Insulin; Male; Mazindol; Obesity; Thyrotr | 1982 |
Appetite depressants: weights and measures.
Topics: Amphetamines; Appetite Depressants; Fenfluramine; Humans; Mazindol; Obesity | 1981 |
Mazindol.
Topics: Adipose Tissue, Brown; Animals; Humans; Indoles; Mazindol; Obesity | 1982 |
[Effect of various methods of treatment of obesity on the hypothalamo-hypophyseal system and thyroid function].
Topics: Adult; Appetite Depressants; Chlorphentermine; Diet, Reducing; Female; Humans; Hypothalamo-Hypophyse | 1981 |
Increased potency and binding of mazindol to putative brain anorectic receptors in obesity-prone rats.
Topics: Amygdala; Animals; Appetite; Autoradiography; Binding Sites; Dose-Response Relationship, Drug; Hypot | 1994 |
No effect of genetic obesity and mazindol on imidazoline I2 binding sites in the brain of Zucker rats.
Topics: Animals; Binding Sites; Brain Chemistry; Clonidine; Dioxanes; Idazoxan; Imidazoline Receptors; Male; | 1993 |
Teronac and teratogenecity.
Topics: Female; Humans; Infant, Newborn; Mazindol; Obesity; Pregnancy; Pregnancy Complications; Teratogens | 1993 |
Location and effect of obesity on putative anorectic binding sites in the rat brain.
Topics: Animals; Appetite Depressants; Autoradiography; Binding Sites; Brain; Diet; Male; Mazindol; Obesity; | 1997 |
Semen-like urethral discharge during the use of mazindol.
Topics: Adult; Appetite Depressants; Humans; Male; Mazindol; Obesity; Semen; Urethra; Urethral Diseases; Uri | 1998 |
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Counseling; Dexfenfluramine; Drug | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
[The role of pharmacotherapy for treatment of obesity in adults].
Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agoni | 2000 |
High performance liquid chromatographic determination of mazindol in human plasma.
Topics: Adult; Appetite Depressants; Calibration; Chromatography, High Pressure Liquid; Female; Humans; Mazi | 2001 |
The effect of mazindol on metabolic and regulatory changes in obese women during weight reduction.
Topics: Adult; Blood Glucose; Body Weight; Diet, Reducing; Energy Metabolism; Epinephrine; Fatty Acids, None | 1979 |
[Obesity and diabetes mellitus].
Topics: Biguanides; Diabetes Mellitus; Diuretics; Female; Humans; Male; Mazindol; Obesity | 1979 |
[Mazindol (AN 448 Sandoz) in ambulatory treatment of obesity; its effect on body composition and adipose tissue].
Topics: Adipose Tissue; Ambulatory Care; Female; Humans; Indoles; Mazindol; Obesity | 1977 |
[Mazindol: a new anorectic drug].
Topics: Humans; Indoles; Mazindol; Obesity | 1978 |
Effect of anorexiant drugs on growth hormone secretion in obese children.
Topics: Adolescent; Anthropometry; Appetite Depressants; Arginine; Child; Diet; Female; Fenfluramine; Glucos | 1978 |
[Activity-mobilizing lipids and blood lipids in patients treated with Mazindol].
Topics: Adolescent; Adult; Body Weight; Female; Humans; Indoles; Lipids; Male; Mazindol; Middle Aged; Obesit | 1978 |
[Mazindol (AN-448): a new non-amphetamine anorectic in the treatment of exogenous obesity].
Topics: Adolescent; Adult; Child; Constipation; Drug Evaluation; Female; Humans; Indoles; Male; Mazindol; Mi | 1977 |
[Mazindol in the treatment of obesity in diabetics (author's transl)].
Topics: Adolescent; Adult; Body Weight; Diabetes Mellitus; Female; Humans; Indoles; Male; Mazindol; Middle A | 1977 |
[Treatment of obesity with mazindol (author's transl)].
Topics: Adult; Diet, Reducing; Female; Humans; Indoles; Male; Mazindol; Middle Aged; Obesity; Rural Populati | 1976 |
The effect of an anorectic agent (Mazindol) on control of obese diabetics.
Topics: Adult; Aged; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Indoles; Ins | 1976 |
[Anorexiant drugs in the ambulant treatment of obese patients (author's transl)].
Topics: Appetite Depressants; Feeding Behavior; Habits; Humans; Indoles; Mazindol; Obesity | 1976 |
A multi-centre trial of mazindol ('Teronac') in general practice in Ireland.
Topics: Adolescent; Adult; Aged; Body Weight; Child; Diet, Reducing; Drug Evaluation; Female; Follow-Up Stud | 1975 |
Effects of mazindol on carbohydrate and insulin metabolism in obesity.
Topics: Glucose; Humans; Indoles; Insulin; Mazindol; Obesity | 1975 |
Effect of an anorectic agent, AN 448 on weight reduction and plasma lipids.
Topics: Adult; Aged; Appetite Depressants; Female; Humans; Indoles; Lipids; Male; Mazindol; Middle Aged; Obe | 1975 |
Endocrine and metabolic disease. Obesity.
Topics: Diet, Reducing; Fenfluramine; Humans; Ileum; Jejunum; Mazindol; Obesity; Phenethylamines; Physical E | 1976 |
[Treatment of obesity using a new anorectic].
Topics: Drug Evaluation; Humans; Indoles; Mazindol; Obesity | 1976 |
Regulation of the anorectic drug recognition site during glucoprivic feeding.
Topics: Alloxan; Animals; Blood Glucose; Cerebral Ventricles; Deoxyglucose; Feeding Behavior; Glucose; Hypot | 1992 |
[Clinical use of mazindol in the treatment of essential obesity].
Topics: Adolescent; Adult; Body Weight; Drug Evaluation; Female; Humans; Indoles; Male; Mazindol; Middle Age | 1987 |
[Drug therapy in obesity].
Topics: Animals; Female; Humans; Hypothalamic Area, Lateral; Indoles; Male; Mazindol; Obesity; Ventromedial | 1988 |
[Evaluation of the effect of mazindol on the motor function of the stomach in obese persons].
Topics: Adult; Depression, Chemical; Female; Gastric Emptying; Humans; Indoles; Mazindol; Obesity | 1988 |
[Evaluation of the effect of mazindol on the metabolism and lipolysis in obese women].
Topics: Adult; Energy Metabolism; Female; Humans; Indoles; Lipolysis; Mazindol; Obesity; Physical Exertion; | 1987 |
[Appetite depressants: do they carry any weight?].
Topics: Appetite Depressants; Diet, Reducing; Feeding Behavior; Fenfluramine; Humans; Mazindol; Obesity | 1987 |
[Effect of eating and mazindol on the pain threshold in obese and lean persons].
Topics: Adult; Eating; Female; Humans; Indoles; Mazindol; Obesity; Pain; Pain Measurement; Sensory Threshold | 1985 |
[Effect of mazindol on insulin and glucagon secretion in ventromedial hypothalamic obese rats].
Topics: Animals; Body Weight; Female; Glucagon; Hypothalamic Diseases; Indoles; Insulin; Insulin Secretion; | 1985 |
Mazindol (Teronac)- another anorectic drug.
Topics: Animals; Appetite Depressants; Humans; Indoles; Mazindol; Obesity | 1974 |